แปลง Pi Network Dog PIDOG เป็น Molecules of Korolchuk IP-NFT VITA-FAST

PIDOG is a community-driven meme coin created with the mission to promote and actively support the Pi Network ecosystem. Designed to be more than just a typical meme coin, PIDOG aims to amplify awareness and foster deeper engagement with the Pi Network by leveraging its fun, relatable, and engaging branding. The project recognizes the immense potential of combining the viral nature of meme culture with the ever-growing crypto community, creating an avenue for Pi Network users to connect with the broader cryptocurrency space in a unique and innovative way. By acting as both a promotional tool and a community symbol, PIDOG seeks to bridge the gap between lighthearted crypto entertainment and meaningful blockchain adoption. Its playful yet purpose-driven approach makes it stand out, ensuring that it not only appeals to crypto enthusiasts but also resonates with Pi Network’s global community of millions of users. Through this synergy, PIDOG continues to grow as a vibrant and influential presence within the crypto landscape.

What is the project about? VitaDAO, a decentralized autonomous organization, introduces VITA-FAST, an innovative funding model for longevity research. Leveraging the Ethereum blockchain, VITA-FAST are ERC-20 tokens, signifying fractional ownership of the Intellectual Property Non-Fungible Token (IP-NFT) from longevity research conducted at the Korolchuk Lab, Newcastle University. VITA-FAST token holders gain governance rights over the IP, democratizing the decision-making processes in scientific research. 1. What is the project about? The project is focused on discovering and developing therapeutic compounds that can reactivate autophagy in Npc1 -/- cells. This involves screening bioactive and commercial small molecules in cell survival assays to identify potential autophagy activators that are not cytotoxic. The project uses advanced techniques like luciferase-p6 clearance and Halo-GFP-LC3 orthogonal assays for this purpose. 2. What makes your project unique? The project's uniqueness lies in its approach to identifying novel compounds that can induce autophagy in NPC1 -/- cells, a crucial process for treating Niemann-Pick Type C disease. Unlike existing treatments, this project employs high-throughput screening methods and innovative assays to discover compounds with high chemical variability and no similarity to existing autophagy inducers, opening up possibilities for new iIP. 3. History of your project. The project, led by Dr. Korolchuk and his team at Newcastle University, has progressed from generating data on thousands of compounds using advanced screening assays to identifying lead compounds with potential autophagic properties. It has evolved to include the synthesis of derivatives of these compounds and is now moving towards drug translation processes, including pharmacokinetics and scalability studies. 4. What’s next for your project? The next steps involve screening third-generation compounds, conducting in vitro and in vivo models using patient